News

News

New CEO Announcement

f(x) Immune Diagnostics, Inc. Announces New CEO For Immediate Release: Candler, NC, December 19, 2017 —f(x) Immune Diagnostics, Inc. today announced that its board of directors has appointed Michael Sowinski, as the Company’s new Chairman of the Board and CEO, effective immediately. “The board is delighted that Mike will lead f(x) Immune into the next stage of growth,” said Socrates Choumbakos, CFO and board

Fx Immune Diagnostics Obtains Exclusive License For Human Anti-S. pneumoniae Monoclonal Antibody Technology

North Carolina Company Completes License Deal Important to the Global Effort Against Pneumococcal Infections For Immediate Release: Candler, NC, November 10, 2017 —f(x) Immune Diagnostics, Inc. has obtained the worldwide exclusive license to provide testing kits, services, and manufacturing of fully human monoclonal antibodies against Streptococcus pneumoniae. The license was obtained from Pamlico Biopharma, Inc. and is based on patents and technologies from the
Fx Immune Diagnostics Obtains Exclusive License For Human Anti-S. pneumoniae Monoclonal Antibody Technology
Categories: News

UNC-Asheville Recieves Grant from NC Biotech Center

Congratulations to UNC-Asheville for successfully completing a competitive grant process through the North Carolina Biotechnology Center.
UNC-Asheville Recieves Grant from NC Biotech Center
Categories: News
f (x) Immune Diagnostics, Inc. | 1463 Sand Hill Rd. Suite 312 | Candler, NC 28715
855-427-2011
All services and products on this site are for in vitro research use only, not for diagnostic or therapeutic use.